Roche to present results of the largest safety study of its kind with Tecentriq (atezolizumab) in patients with metastatic bladder cancer
Roche today announced first results from SAUL, a Phase IIIb study evaluating the safety of Tecentriq ® in approximately 1000 patients with locally advanced or metastatic urothelial carcinoma (mUC) including several clinically relevant populations reflective of real-world clinical practice (patients with renal impairment, poor performance status (ECOG PS 2), treated asymptomatic CNS metastases, sta ble controlled autoimmune disease).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Pharmaceuticals | Study